Novavax COVID-19 vaccine, adjuvanted (2023-2024 formula) – Emergency Use Authorization
October 3, 2023 - The FDA granted emergency use authorization (EUA) for Novavax’s Novavax COVID-19 vaccine, adjuvanted (2023-2024 formula), for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older.
Top